Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Pharmacol Ther. 2018 Oct 19;195:100–110. doi: 10.1016/j.pharmthera.2018.10.010

Figure 1. Selective human 12-LOX inhibitors and human 12/15-LOX dual inhibitor.

Figure 1.

Shown are the structures of selective human 12-LOX inhibitors: 0-hydroxyquinoline-based ML127 and N-(benzo[d]thiazol-2-yl)-4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide ML355. Also shown is the 12/15-LOX dual inhibitor ML351, which is an amine oxazol.